<SEC-DOCUMENT>0001157523-16-007390.txt : 20161116
<SEC-HEADER>0001157523-16-007390.hdr.sgml : 20161116
<ACCEPTANCE-DATETIME>20161116080015
ACCESSION NUMBER:		0001157523-16-007390
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20161116
FILED AS OF DATE:		20161116
DATE AS OF CHANGE:		20161116

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aurinia Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001600620
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36421
		FILM NUMBER:		162001349

	BUSINESS ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
		BUSINESS PHONE:		250-708-4272

	MAIL ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a51461696.htm
<DESCRIPTION>AURINIA PHARMACEUTICALS INC. 6-K
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2016 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-family: Times New Roman; font-size: 10pt">
    <p style="text-align: center">
      <br>
      <font style="font-size: 16pt; font-family: Times New Roman"><b>UNITED
      STATES</b></font><b><font style="font-size: 16pt; font-family: Times New Roman"><br style="font-family: Times New Roman; font-size: 16pt"></font><font style="font-size: 16pt; font-family: Times New Roman">SECURITIES
      AND EXCHANGE COMMISSION</font></b><br><font style="font-size: 10pt; font-family: Times New Roman"><b>Washington,
      D.C. 20549</b></font>
    </p>
    <hr style="text-align: center; color: #000000; height: 1.0 pt; width: 100%">


    <p style="text-align: center">
      <font style="font-size: 14pt; font-family: Times New Roman"><b>FORM 6-K</b></font>
    </p>
    <hr style="text-align: center; color: #000000; height: 1.0 pt; width: 100%">


    <p style="text-align: center">
      <font style="font-family: Times New Roman"><b>&#160;</b></font><b><font style="font-size: 12pt; font-family: Times New Roman">REPORT
      OF FOREIGN PRIVATE ISSUER</font></b><br><font style="font-size: 12pt; font-family: Times New Roman"><b>PURSUANT
      TO RULE 13A-16 OR 15D-16 UNDER THE</b></font><br><font style="font-size: 12pt; font-family: Times New Roman"><b>SECURITIES
      EXCHANGE ACT OF 1934</b></font><br><br><font style="font-size: 10pt; font-family: Times New Roman"><b>Dated</b></font><font style="font-size: 10pt; font-family: Times New Roman">
      </font><font style="font-size: 10pt; font-family: Times New Roman"><b>November
      16, 2016</b></font><br><br><font style="font-size: 10pt; font-family: Times New Roman"><b>Commission
      File Number</b></font><b> 001-36421</b>
    </p>
    <hr style="text-align: center; color: #000000; height: 1.0 pt; width: 100%">


    <p style="text-align: center">
      <font style="font-size: 24pt"><b>AURINIA PHARMACEUTICALS INC.</b></font><br><b>(Exact
      name of Registrant as specified in its charter)</b><br><br>
    </p>
    <hr style="text-align: center; color: #000000; height: 1.0 pt; width: 100%">


    <p style="text-align: center">
      <b>N/A</b><br><b>(Translation of Registrant&#8217;s Name)</b><br><br>
    </p>
    <p style="text-align: center">
      <b>#1203-4464 Markham Street</b><br><b>Victoria, British Columbia</b><br><b>V8Z7X8</b><br><b>(250)
      708-4272</b><br><b>(Address and telephone number of registrant&#8217;s
      principal executive offices)</b>
    </p>
    <p style="text-align: center">

    </p>
    <hr style="text-align: center; color: #000000; height: 1.0 pt; width: 100%">


    <p style="text-align: left; text-indent: 30.0px">
      <font style="font-size: 10pt; font-family: Times New Roman">Indicate by
      check mark whether the registrant files or will file annual reports
      under cover of Form 20-F or Form 40-F:</font>
    </p>
    <p style="text-align: center">
      <font style="font-size: 10pt; font-family: Times New Roman">Form 20-F &#160;</font><font style="font-size: 12pt; font-family: Arial Unicode MS">&#8414;</font><font style="font-size: 10pt; font-family: Times New Roman">
      &#160;&#160;&#160;&#160;Form 40-F&#160; </font><font style="font-size: 12pt; font-family: Arial Unicode MS">&#8864;</font>
    </p>
    <p style="text-align: left; text-indent: 30.0px">
      <font style="font-size: 10pt; font-family: Times New Roman">Indicate by
      check mark if the registrant is submitting the Form 6-K in paper as
      permitted by Regulation S-T Rule 101(b)(1):&#160;</font><font style="font-size: 12pt; font-family: Arial Unicode MS">&#8414;</font><br>
    </p>
    <p style="text-align: left; text-indent: 30.0px">
      <font style="font-size: 10pt; font-family: Times New Roman">Indicate by
      check mark if the registrant is submitting the Form 6-K in paper as
      permitted by Regulation S-T Rule 101(b)(7):&#160;</font><font style="font-size: 12pt; font-family: Arial Unicode MS">&#8414;</font><br>
    </p>
    <p style="text-align: justify; text-indent: 30.0px">
      <font style="font-size: 10pt; font-family: Times New Roman">Indicate by
      check mark whether by furnishing the information contained in this Form,
      the registrant is also thereby furnishing the information to the
      Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act
      of 1934.</font>
    </p>
    <p style="text-align: center">
      <font style="font-size: 10pt; font-family: Times New Roman">Yes &#160;</font><font style="font-size: 12pt; font-family: Arial Unicode MS">&#8864;</font><font style="font-size: 12pt">&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: Times New Roman">
      No &#160;</font><font style="font-size: 12pt; font-family: Arial Unicode MS">&#8414;</font>
    </p>
    <p style="text-indent: 30.0px; font-size: 10pt">
      This Form 6-K is hereby filed and incorporated by reference into the
      Registrant&#8217;s Registration Statement on Form F-10 (File No. 333-206994).
    </p>
    <div style="margin-left: 0pt; margin-right: 0pt; width: 100%; text-indent: 0pt; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-align: center">
      <font style="font-size: 10pt; font-family: Times New Roman"><br style="font-size: 10pt; font-family: Times New Roman">
      </font><font style="font-size: 10pt; font-family: Times New Roman"><b>SIGNATURES</b></font>
    </p>
    <p style="text-indent: 30.0px">
      <font style="font-size: 10pt; font-family: Times New Roman">Pursuant to
      the requirements of the Securities Exchange Act of 1934, the registrant
      has duly caused this report to be signed on its behalf by the
      undersigned, thereunto duly authorized.</font>
    </p>
<div style="text-align:left">
    <table style="font-size: 10pt; width: 100%; font-family: Times New Roman; margin-bottom: 10.0px" cellspacing="0">
      <tr>
        <td valign="top" style="padding-left: 0.0px; text-align: left; width: 6%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Dated:
          </p>
        </td>
        <td valign="top" style="padding-left: 0.0px; text-align: left; width: 44%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            November 16, 2016
          </p>
        </td>
        <td colspan="3">

        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 44%">

        </td>
        <td colspan="3">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 44%">

        </td>
        <td valign="top" style="padding-left: 0.0px; text-align: left" colspan="3">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>Aurinia Pharmaceuticals Inc.</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 44%">

        </td>
        <td valign="top" style="padding-left: 0.0px; text-align: center" colspan="3">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
      </tr>
      <tr>
        <td valign="top" style="padding-left: 0.0px; padding-bottom: 2.0px; text-align: left; width: 6%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
        <td valign="top" style="padding-left: 0.0px; padding-bottom: 2.0px; text-align: left; width: 44%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
        <td valign="top" style="padding-left: 0.0px; padding-bottom: 2.0px; text-align: left; width: 3%">
          By:
        </td>
        <td valign="top" style="border-bottom-color: black; padding-left: 0.0px; border-bottom-width: 1.0pt; text-align: left; border-bottom-style: solid" colspan="2">
          <p style="margin-top: 0px; margin-bottom: 0px">
            /s/ Michael R. Martin
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 44%">

        </td>
        <td valign="top" style="padding-left: 0.0px; text-align: left; width: 3%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
        <td valign="top" style="padding-left: 0.0px; text-align: left; width: 5%">
          Name:
        </td>
        <td valign="top" style="padding-left: 0.0px; text-align: left; width: 42%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Michael R. Martin
          </p>
        </td>
      </tr>
      <tr>
        <td valign="top" style="padding-left: 0.0px; text-align: left; width: 6%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
        <td valign="top" style="padding-left: 0.0px; text-align: left; width: 44%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
        <td style="width: 3%">

        </td>
        <td valign="top" style="padding-left: 0.0px; text-align: left; width: 5%">
          Title:
        </td>
        <td valign="top" style="padding-left: 0.0px; text-align: left; width: 42%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Chief Operating Officer
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p style="text-align: center">

    </p>
    <div style="margin-left: 0pt; margin-right: 0pt; text-indent: 0pt; width: 100%; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center; font-size: 10pt; font-family: Times New Roman">
          2
        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-align: center">

    </p>
    <p style="text-align: center">
      <b>EXHIBIT&#160;INDEX</b>
    </p>
<div style="text-align:left">
    <table style="font-size: 10pt; width: 100%; font-family: Times New Roman; margin-bottom: 10.0px" cellspacing="0">
      <tr>
        <td valign="bottom" style="border-bottom-color: black; padding-left: 0.0px; border-bottom-width: 1.0pt; text-align: left; width: 7%; border-bottom-style: solid">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>Exhibit</b>
          </p>
        </td>
        <td valign="bottom" style="padding-left: 0.0px; padding-bottom: 2.0px; text-align: left; width: 5%">
          &#160;
        </td>
        <td valign="bottom" style="border-bottom-color: black; padding-left: 0.0px; border-bottom-width: 1.0pt; text-align: left; width: 88%; border-bottom-style: solid">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>Description of Exhibit</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 7%">

        </td>
        <td style="width: 5%">

        </td>
        <td valign="top" style="padding-left: 0.0px; text-align: left; width: 88%">
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="padding-left: 0.0px; padding-right: 0.0px; text-align: left; width: 7%; white-space: nowrap">
          99.1
        </td>
        <td style="width: 5%">

        </td>
        <td valign="top" style="padding-left: 0.0px; text-align: left; width: 88%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            News Release &#8211; Aurinia Highlights Speed of Remission From Global
            Phase IIB AURA Study of Voclosporin at 2016 American College of
            Rheumatology Annual Meeting
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p>
      Exhibit 99.1 included with this report on Form 6-K is hereby
      incorporated by reference as an exhibit to the Registrant&#8217;s Registration
      Statement on Form F-10 (File No. 333-206994), as amended or supplemented.
    </p>
    <p>

    </p>
    <p style="text-align: center">
      3
    </p>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a51461696ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2016 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-family: Times New Roman; font-size: 8pt">
    <p style="text-align: right">
      <b>Exhibit 99.1</b>
    </p>
    <p style="text-align: center">
      <font style="font-size: 12pt; font-family: Times New Roman"><b>Aurinia
      Highlights Speed of Remission from Global Phase IIb AURA Study of
      Voclosporin in Lupus Nephritis at 2016 American College of Rheumatology
      Annual Meeting</b></font>
    </p>
    <p style="text-align: center">
      <i><font style="font-size: 12pt; font-family: Times New Roman"><b>Late
      breaking abstract showcases</b></font></i><b><font style="font-size: 12pt; font-family: Times New Roman">
      </font><i><font style="font-size: 12pt; font-family: Times New Roman">first
      global study of active lupus nephritis to meet its primary endpoint,
      presented on November 15</font><sup><font style="font-size: 12pt; font-family: Times New Roman">th</font></sup></i></b>
    </p>
    <p>
      VICTORIA, British Columbia--(BUSINESS WIRE)--November 16, 2016--Aurinia
      Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (&#8220;Aurinia&#8221; or the
      &#8220;Company&#8221;), a clinical stage biopharmaceutical company focused on the
      global immunology market, today highlighted additional findings from its
      global Phase IIb AURA study of voclosporin in the treatment of lupus
      nephritis (LN). The abstract was presented at the American College of
      Rheumatology and Association of Rheumatology Health Professionals
      (ACR/ARHP) Annual Meeting in Washington, D.C. during the Late-Breaking
      News session on November 15, 2016.
    </p>
    <p>
      The late-breaking abstract, titled, &#8220;Speed of Remission with the Use of
      Voclosporin, MMF and Low Dose Steroids: Results of a Global Lupus
      Nephritis Study,&#8221; was presented by Mary Anne Dooley, M.D., M.P.H., of
      the University of North Carolina Kidney Center. The global Phase IIb
      AURA study of voclosporin, a novel immunosuppressant that has been
      applied as a treatment for LN, is the first global active lupus
      nephritis study to meet its primary endpoint. In addition, all secondary
      endpoints in AURA were met, including demonstrating a more rapid
      response rate for patients receiving voclosporin versus patients in the
      control arm with most patients achieving complete remission (CR) at or
      before the eighth week of the trial.
    </p>
    <p>
      &#8220;Lupus nephritis is a devastating, often overlooked disease that
      severely impacts a patient&#8217;s quality of life and, in the worst cases,
      can lead to end-stage renal disease or even death,&#8221; said Dr. Dooley.
      &#8220;The ability to get more patients into remission and in a shorter period
      of time than the current standard of care can have a significant impact
      on the long-term outcomes for these patients. We have demonstrated that
      voclosporin successfully achieves not only higher complete remission
      rates but does so more rapidly in patients with LN. I believe this
      promising data has the potential to shift the standard of care and
      improve long-term outcomes for patients with LN.&#8221;
    </p>
<div style="text-align:left">
    <table style="font-size: 8pt; width: 100%; font-family: Times New Roman; margin-bottom: 10.0px" cellspacing="0">
      <tr>
        <td style="border-bottom-color: black; border-bottom-width: 1.0pt; border-bottom-style: solid">
          &#160;
        </td>
        <td style="border-bottom-color: black; border-bottom-width: 1.0pt; border-bottom-style: solid">
          &#160;
        </td>
        <td style="border-bottom-color: black; border-bottom-width: 1.0pt; border-bottom-style: solid">
          &#160;
        </td>
        <td style="border-bottom-color: black; border-bottom-width: 1.0pt; border-bottom-style: solid">
          &#160;
        </td>
        <td style="border-bottom-color: black; border-bottom-width: 1.0pt; border-bottom-style: solid">
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="middle" style="border-bottom-color: black; padding-left: 0.0px; border-bottom-width: 1.0pt; text-align: center; border-bottom-style: solid">
          <b>Speed of Remission Analyses</b>
        </td>
        <td style="border-bottom-color: black; border-bottom-width: 1.0pt; border-bottom-style: solid">
          &#160;
        </td>
        <td valign="middle" style="border-bottom-color: black; padding-left: 0.0px; border-bottom-width: 1.0pt; text-align: center; border-bottom-style: solid">
          <b>Control</b>
        </td>
        <td style="border-bottom-color: black; border-bottom-width: 1.0pt; border-bottom-style: solid">
          &#160;
        </td>
        <td valign="middle" style="border-bottom-color: black; padding-left: 0.0px; border-bottom-width: 1.0pt; padding-right: 0.0px; text-align: center; border-bottom-style: solid; white-space: nowrap">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>Voclosporin</b><br><b>23.7mg BID</b>
          </p>
        </td>
      </tr>
      <tr>
        <td valign="middle" style="border-bottom-color: black; padding-left: 0.0px; border-bottom-width: 1.0pt; text-align: left; border-bottom-style: solid">
          <b>Post-hoc Responder Analysis </b>(Median time to CR for those who
          achieve CR)
        </td>
        <td style="border-bottom-color: black; border-bottom-width: 1.0pt; border-bottom-style: solid">
          &#160;
        </td>
        <td valign="middle" style="border-bottom-color: black; padding-left: 0.0px; border-bottom-width: 1.0pt; text-align: center; border-bottom-style: solid">
          12 weeks
        </td>
        <td style="border-bottom-color: black; border-bottom-width: 1.0pt; border-bottom-style: solid">
          &#160;
        </td>
        <td valign="middle" style="border-bottom-color: black; padding-left: 0.0px; border-bottom-width: 1.0pt; text-align: center; border-bottom-style: solid">
          7.3 weeks
        </td>
      </tr>
      <tr>
        <td rowspan="2" valign="middle" style="border-bottom-color: black; padding-left: 0.0px; border-bottom-width: 1.0pt; text-align: left; border-bottom-style: solid">
          <b>Pre-Specified Endpoint: Time to Complete Remission (TTCR) </b>[median]
        </td>
        <td>
          &#160;
        </td>
        <td rowspan="2" valign="middle" style="border-bottom-color: black; padding-left: 0.0px; border-bottom-width: 1.0pt; text-align: center; border-bottom-style: solid">
          Not achieved
        </td>
        <td>
          &#160;
        </td>
        <td valign="middle" style="border-bottom-color: black; padding-left: 0.0px; border-bottom-width: 1.0pt; text-align: center; border-bottom-style: solid">
          19.7 weeks
        </td>
      </tr>
      <tr>
        <td style="border-bottom-color: black; border-bottom-width: 1.0pt; border-bottom-style: solid">
          &#160;
        </td>
        <td style="border-bottom-color: black; border-bottom-width: 1.0pt; border-bottom-style: solid">
          &#160;
        </td>
        <td valign="middle" style="border-bottom-color: black; padding-left: 0.0px; border-bottom-width: 1.0pt; text-align: center; border-bottom-style: solid">
          <i><b>p&lt;.001</b></i>
        </td>
      </tr>
      <tr>
        <td rowspan="2" valign="middle" style="border-bottom-color: black; padding-left: 0.0px; border-bottom-width: 1.0pt; text-align: left; border-bottom-style: solid">
          <b>Pre-Specified Endpoint: Time to Partial Remission (TTPR) </b>[median]
        </td>
        <td>

        </td>
        <td rowspan="2" valign="middle" style="border-bottom-color: black; padding-left: 0.0px; border-bottom-width: 1.0pt; text-align: center; border-bottom-style: solid">
          6.6 weeks
        </td>
        <td>

        </td>
        <td valign="middle" style="border-bottom-color: black; padding-left: 0.0px; border-bottom-width: 1.0pt; text-align: center; border-bottom-style: solid">
          4.1 weeks
        </td>
      </tr>
      <tr>
        <td style="border-bottom-color: black; border-bottom-width: 1.0pt; border-bottom-style: solid">
          &#160;
        </td>
        <td style="border-bottom-color: black; border-bottom-width: 1.0pt; border-bottom-style: solid">
          &#160;
        </td>
        <td valign="bottom" style="border-bottom-color: black; padding-left: 0.0px; border-bottom-width: 1.0pt; padding-right: 0.0px; text-align: center; border-bottom-style: solid; white-space: nowrap">
          <i><b>p=.002</b></i>
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
      </tr>
    </table>
    </div>
    <p>
      &#8220;This promising data emphasizes the importance of enhancing the
      treatment options available for this debilitating disease,&#8221; said Neil
      Solomons, M.D., Aurinia&#8217;s Chief Medical Officer. &#8220;The speed in which
      patients achieved CR, which is consistent with our open-label AURION
      study, is encouraging and we are absolutely delighted by the medical
      community&#8217;s reception to the data. We remain focused on advancing the
      clinical development program for voclosporin, fulfilling our goal of
      improving long-term outcomes for patients.&#8221;
    </p>
    <p>
      The AURA study enrolled 265 patients in 20 countries using low (23.7 mg
      BID), high dose voclosporin (39.5 mg BID) or placebo added to standard
      of care of mycophenolate mofetil (MMF) and steroids in active LN. The
      study met its primary endpoint with statistically significant complete
      remission rates in the 23.7mg BID arm, and demonstrated statistically
      significant improvements across all secondary endpoints: Partial
      Remission (PR); time to CR and PR; reduction in Systemic Lupus
      Erythematosus Disease Activity Index or SLEDAI score; and reduction in
      UPCR over the 24-week treatment period.
    </p>
    <p>
      Adverse events were higher in the voclosporin treatment arms versus the
      control arm, which is consistent with increased immunosuppression. The
      overall mortality rate was similar to other recent global LN trials; all
      were considered unrelated to the study drug. The AURA study remains
      ongoing until its 48-week secondary endpoints, which will be available
      in Q1 2017.
    </p>
    <p>
      Based on recent FDA feedback, Aurinia expects to initiate a single Phase
      III clinical trial of voclosporin 23.7mg BID (AURORA) in Q2 2017.
      Aurinia believes this Phase III clinical trial whose design is
      consistent with the ongoing AURA study, will support a New Drug
      Application (NDA) submission.
    </p>
    <div style="margin-left: 0pt; margin-right: 0pt; text-indent: 0pt; width: 100%; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      <i><b>About AURION</b></i>
    </p>
    <p>
      The AURION study or &#8220;Aurinia Early Urinary Protein Reduction Predicts
      Response Study&#8221; is an open-label, exploratory study being conducted in
      multiple sites in Malaysia to assess the short term predictors of
      response using voclosporin (23.7mg) in combination with mycophenolate
      mofetil and oral corticosteroids in patients with active lupus
      nephritis. This study will examine biomarkers of disease activity at 8
      weeks and their ability to predict response at 24 and 48 weeks.
    </p>
    <p>
      <i><b>About AURORA</b></i>
    </p>
    <p>
      The AURORA study is a 52-week global double-blind placebo controlled
      phase III study that will compare the efficacy of one dose of
      voclosporin (23.7mg BID) or placebo added to current standard of care of
      mycophenolate mofetil (MMF, also known as CellCept&#174;) in achieving renal
      response (formerly referred to as complete remission) in patients with
      active LN. Both arms will also receive low doses of corticosteroids as
      part of background therapy after a stringent taper.
    </p>
    <p>
      <i><b>About Voclosporin</b></i>
    </p>
    <p>
      Voclosporin, an investigational drug, is a novel and potentially
      best-in-class calcineurin inhibitor (&#8220;CNI&#8221;) with clinical data in over
      2,000 patients across indications. Voclosporin is an immunosuppressant,
      with a synergistic and dual mechanism of action that has the potential
      to improve near- and long-term outcomes in LN when added to standard of
      care (MMF). By inhibiting calcineurin, voclosporin blocks IL-2
      expression and T-cell mediated immune responses. It is made by a
      modification of a single amino acid of the cyclosporine molecule which
      has shown a more predictable pharmacokinetic and pharmacodynamic
      relationship, an increase in potency, an altered metabolic profile, and
      potential for flat dosing. The Company anticipates that upon regulatory
      approval, patent protection for voclosporin will be extended in the
      United States and certain other major markets, including Europe and
      Japan, until at least October 2027 under the Hatch-Waxman Act and
      comparable laws in other countries.
    </p>
    <p>
      <i><b>About Lupus Nephritis (LN)</b></i>
    </p>
    <p>
      Lupus Nephritis (LN) in an inflammation of the kidney caused by Systemic
      Lupus Erythematosus (SLE) and represents a serious progression of SLE.
      SLE is a chronic, complex and often disabling disorder and affects more
      than 500,000 people in the United States (mostly women). The disease is
      highly heterogeneous, affecting a wide range of organs &amp; tissue systems.
      It is estimated that as many as 60% of all SLE patients have clinical LN
      requiring treatment. Unlike SLE, LN has straightforward disease outcomes
      where an early response correlates with long-term outcomes, measured by
      proteinuria. In patients with LN, renal damage results in proteinuria
      and/or hematuria and a decrease in renal function as evidenced by
      reduced estimated glomerular filtration rate (eGFR), and increased serum
      creatinine levels. LN is debilitating and costly and if poorly
      controlled, LN can lead to permanent and irreversible tissue damage
      within the kidney, resulting in end-stage renal disease (ESRD), thus
      making LN a serious and potentially life-threatening condition.
    </p>
    <p>
      <i><b>About Aurinia</b></i>
    </p>
    <p>
      Aurinia is a clinical stage biopharmaceutical company focused on
      developing and commercializing therapies to treat targeted patient
      populations that are suffering from serious diseases with a high unmet
      medical need. The Company is currently developing voclosporin, an
      investigational drug, for the treatment of lupus nephritis (LN). The
      Company is headquartered in Victoria, BC and focuses its development
      efforts globally. Visit <u>www.auriniapharma.com</u> for more
      information.
    </p>
    <p>
      <i><b>Forward Looking Statements</b></i>
    </p>
    <p>
      This press release contains forward-looking statements, including
      statements related to Aurinia's regulatory strategy, Aurinia's analysis,
      assessment and conclusions of the results of the AURA-LV clinical study,
      and the efficacy and commercial potential of voclosporin. It is possible
      that such results or conclusions may change based on further analyses of
      these data. Words such as &quot;plans,&quot; &quot;intends,&quot; &#8220;may,&#8221; &quot;will,&quot; &quot;believe,&quot;
      and similar expressions are intended to identify forward-looking
      statements. These forward-looking statements are based upon Aurinia&#8217;s
      current expectations. Forward-looking statements involve risks and
      uncertainties. Aurinia&#8217;s actual results and the timing of events could
      differ materially from those anticipated in such forward-looking
      statements as a result of these risks and uncertainties, which include,
      without limitation, the risk that Aurinia&#8217;s analyses, assessment and
      conclusions of the results of the AURA-LV clinical study set forth in
      this release may change based on further analyses of such data, and the
      risk that Aurinia&#8217;s clinical studies for voclosporin may not lead to
      regulatory approval. These and other risk factors are discussed under
      &quot;Risk Factors&quot; and elsewhere in Aurinia&#8217;s Annual Information Form for
      the year ended December 31, 2015 filed with Canadian securities
      authorities and available at <u>www.sedar.com</u> and on Form 40-F with
      the U.S. Securities Exchange Commission and available at <u>www.sec.gov</u>,
      each as updated by subsequent filings, including filings on Form 6-K.
      Aurinia expressly disclaims any obligation or undertaking to release
      publicly any updates or revisions to any forward-looking statements
      contained herein to reflect any change in Aurinia's expectations with
      regard thereto or any change in events, conditions or circumstances on
      which any such statements are based.
    </p>
    <p>

    </p>
    <p>
      CONTACT:<br>Aurinia Pharmaceuticals Inc.<br>Celia Economides<br>Head of
      IR &amp; Communications<br><u>ceconomides@auriniapharma.com</u>
    </p>
    <p>

    </p>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
